A Phase 1 Study of LY2584702 in Japanese Patients with Solid Tumors

Eli Lilly Japan K.K.0 个研究点开始时间: 2010年11月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Have histological or cytological evidence of a diagnosis of advanced and/or metastatic cancer (solid tumors) that is refractory to standard therapy and/or therapies known to provide clinical benefit, or for which no standard therapy exists.
•Have the presence of disease amenable to efficacy assessment as defined by the Response Evaluation Criteria In Solid Tumors(RECIST). Japanese patients who have advanced non-measurable disease with elevation of a validated tumor marker may be eligible, if discussed and agreed upon by the investigator and Lilly.
•Have adequate organ function including.
•Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group scale.
•Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy prior to study enrollment and recovered from the acute effects of therapy.
•Have an estimated life expectancy of 12 weeks or greater.
•Are able to swallow capsules.

发起方